LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma
The ultimate clinical aim of this proposed phase I trial is to evaluate the toxicity and determine the recommended phase II dose of combining the effect of LDFWART following administration of docetaxel for 6 cycles in patients with recurrent platinum-resistant ovarian cancer.
Ovarian Cancer|Ovarian Carcinoma|Recurrent Ovarian Cancer|Recurrent Ovarian Carcinoma
RADIATION: Low Dose Fractionated Whole Abdominal Radiation Therapy|DRUG: Docetaxel
Number of Subjects Experiencing Adverse Events as a Measure of Safety and Tolerability, Number of subjects experiencing adverse events after receiving protocol therapy., 3 years|Recommended Phase II Dose of LDFWART, The recommended phase II dose of low-dose whole abdominal radiation therapy (LDFWART) when used in conjunction with 6 cycles of docetaxel chemotherapy., 3 years
Number of Subjects Experiencing Complete or Partial Response to Protocol Therapy, Number of subjects experiencing complete response (CR) or partial response (PR) according to RECIST Criteria Version 1.1, Up to 5 years|The rate of Overall Survival in subjects receiving protocol therapy, Observed length of life from start of treatment to cause of death, Up to 5 years|The rate of Progression-Free Survival in subjects receiving protocol therapy., Length of time from start of treatment to the time of documented disease progression in study subjects, Up to 5 years
The ultimate clinical aim of this proposed phase I trial is to evaluate the toxicity and determine the recommended phase II dose of combining the effect of LDFWART following administration of docetaxel for 6 cycles in patients with recurrent platinum-resistant ovarian cancer.